DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-21-0600; Docket No. CDC-2021-0087]

Proposed Data Collection Submitted for Public Comment and Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice with comment period.

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled CDC Model Performance Evaluation Program (MPEP) for Mycobacterium tuberculosis Susceptibility Testing information collection. CDC is requesting a three-year approval for revision to the previously approved project used to monitor and evaluate performances and practices among national laboratories for M. tuberculosis susceptibility testing.

DATES: CDC must receive written comments on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER].

ADDRESSES: You may submit comments, identified by Docket No. CDC-2021-0087 by any of the following methods:
• Federal eRulemaking Portal: Regulations.gov. Follow the instructions for submitting comments.

• Mail: Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road, N.E., MS-D74, Atlanta, Georgia 30329.

Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to Regulations.gov.

Please note: Submit all comments through the Federal eRulemaking portal (regulations.gov) or by U.S. mail to the address listed above.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road, N.E., MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; E-mail: omb@cdc.gov.

SUPPLEMENTARY INFORMATION:

Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each
proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below.

The OMB is particularly interested in comments that will help:

1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

2. Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

3. Enhance the quality, utility, and clarity of the information to be collected;

4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses; and

5. Assess information collection costs.

Proposed Project
CDC Model Performance Evaluation Program (MPEP) for
*Mycobacterium tuberculosis* Susceptibility testing (OMB Control
No. 0920-0600, Exp. 2/20/2022) – Revision – National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and Prevention (CDC).

**Background and Brief Description**

The Centers for Disease Control and Prevention (CDC) is
requesting a revision to approved information collection from
participants in the CDC Model Performance for *Mycobacterium
tuberculosis* Drug Susceptibility Testing Program for a period of
three years. Revision of this information will not require
changes in the scope of the project. This Revision includes; (a)
modification of the Instructions to Participants Letter; (b)
modification of the MPEP *Mycobacterium tuberculosis* Results
Worksheet; (c) modification of online data collection
instrument; (d) modification of the MPEP *Mycobacterium
tuberculosis* Minimum Inhibitory Concentration Results Worksheet;
(e) removal of Reminder Telephone Script; and (f) modification
of Aggregate Report Letter.

While the overall number of cases of TB in the U.S. has
decreased, rates still remain high among foreign-born persons,
corrections, homeless populations, and individuals infected with
HIV in major metropolitan areas. To reach the goal of
eliminating TB, the Model Performance Evaluation Program for
*Mycobacterium tuberculosis* susceptibility testing is used to
monitor and evaluate performance and practices among US laboratories performing *M. tuberculosis* susceptibility testing. Participation in this program is one way laboratories can ensure high-quality laboratory testing, resulting in accurate and reliable testing results.

By providing an evaluation program to assess the ability of laboratories to test for drug resistant *M. tuberculosis* strains, CDC gives laboratories a self-assessment tool to aid in optimizing their skills in susceptibility testing. The information obtained from the laboratories on susceptibility practices and procedures is used to establish variables related to good performance, assess training needs, and aid with the development of practice standards.

Participants in this program include domestic clinical and public health laboratories. Data collection from laboratory participants occurs twice per year. The data collected in this program will include the susceptibility test results of primary and secondary drugs, drug concentrations, and test methods performed by laboratories on a set of performance evaluation (PE) isolates. The PE isolates are sent to participants twice a year, and participants also report demographic data such as laboratory type and the number of drug susceptibility tests performed annually.

CDC requests approval for an estimated 129 burden hours annually. There is no cost to respondents to participate other than their time.
## Estimated Annualized Burden Hours

<table>
<thead>
<tr>
<th>Type of Respondents</th>
<th>Form Name</th>
<th>Number of Respondents</th>
<th>Number of Responses per Respondent</th>
<th>Average Burden per Response (in hours)</th>
<th>Total Burden (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domestic Laboratory</td>
<td>Participant Biosafety Compliance Letter of Agreement</td>
<td>80</td>
<td>1</td>
<td>5/60</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>MPEP Mycobacterium tuberculosis Results Worksheet</td>
<td>80</td>
<td>2</td>
<td>30/60</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Online Survey Instrument</td>
<td>80</td>
<td>2</td>
<td>15/60</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>MPEP Mycobacterium tuberculosis Minimum Inhibitory Concentration Results Form</td>
<td>4</td>
<td>2</td>
<td>15/60</td>
<td>2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>129</strong></td>
</tr>
</tbody>
</table>

**Jeffrey M. Zirger,**  
Lead,  
Information Collection Review Office,  
Office of Scientific Integrity,  
Office of Science,  
Centers for Disease Control and Prevention.

[FR Doc. 2021-18541 Filed: 8/26/2021 8:45 am; Publication Date: 8/27/2021]